Literature DB >> 6202243

[Acute cardiotoxicity of anthracyclines--analysis by using Holter ECG].

K Okuma, I Furuta, K Ota.   

Abstract

To investigate the detailed acute cardiotoxicity of the anthracycline antibiotics, adriamycin (ADM) and a tetrahydropyranyl derivative (THP-ADM), Holter ECG was recorded and some of the electrocardiographic parameters were analyzed. The basic rhythm was sinus rhythm in many cases except only one case which developed intermittent atrial fibrillation after the administration of ADM. No effect on the specialized conduction system was observed in either ADM or TH-PADM. In relation to the supraventricular premature beat, no increase of the pre-existing supraventricular extrasystole and fresh appearance of the supraventricular extrasystole were observed after the administration of these drugs. On the other hand, the ventricular premature beat was tended to increase after ADM administration, and the mode of appearance of the ventricular extrasystole was very dangerous and life-threatening. For example, short-run type and R on T type ventricular extrasystole were recorded. THP-ADM induced no significant increase of the ventricular extrasystole. The developed ST-T changes were seen after the administration of these drugs, but the patients complained neither the symptoms of heart failure nor stenocardia. In conclusion. THP-ADM had less cardiotoxicity than ADM.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202243

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  4 in total

1.  A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies.

Authors:  K Yamada; S Shirakawa; R Ohno; H Yamada; Y Hirota; K Ohara; K Yamagata; M Kobayashi; M Hirano; Y Ikeda
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850

2.  Comparison of acute effects of anthracyclines on cardiac electrophysiological parameters of isolated guinea-pig hearts.

Authors:  G Stark; U Stark; H Samonigg; K Kasparek; A Lueger; S Nagl; H Bertuch; E Pilger; H A Tritthart
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Phase II trial of pirarubicin in the treatment of advanced bladder cancer.

Authors:  M Mahjoubi; J Kattan; M Ghosn; J P Droz; I Philippot; P Herait
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

4.  Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial.

Authors:  Robin Chung; Angshuman Maulik; Ashraf Hamarneh; Daniel Hochhauser; Derek J Hausenloy; J Malcolm Walker; Derek M Yellon
Journal:  Clin Cardiol       Date:  2016-01-25       Impact factor: 2.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.